Patient P-03244
Therapy response
Stable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
29%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S08
- Day 14 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 18 DT-01 recommended — Dosing / Timing Recommendation DT-01
- Day 19 Patient accepted — Started DT-01 in the companion
- Day 24 GI symptom burden −23% vs expected — Dosing / Timing Recommendation DT-01
- Day 30 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 14.
Primary contributors, last 14 days
- GI instability+13
- Inflammatory activity+13
- Nutritional resilience-10
- Treatment adherence+5
What helped?
- Dosing / Timing Recommendation DT-01Day 18Result: symptom burden −23%
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients.
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓60
- MicrobiomeButyrate capacity 27/100
- MicrobiomeF. prausnitzii depleted
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Inflammatory signalling ↑25
- DNAIL6 -174 variant raises baseline inflammatory tone
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2 · butyrate capacity 27/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 7.4 h
- Steps
- 4,836
- Resting HR
- 62 bpm
Daily log: GI score 18, nutritional resilience 65, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03442 | 54% | S11 | DT-01 | improved | 51 |
| P-03317 | 49% | S08 | HY-01 | improved | 45 |
| P-03215 | 48% | S16 | HY-01 | improved | 44 |
| P-03408 | 48% | S09 | HY-01 | improved | 53 |
| P-03143 | 46% | S11 | DT-01 | improved | 49 |
| P-03255 | 46% | S01 | HY-01 | improved | 53 |
| P-03040 | 45% | S03 | — | — | 51 |
| P-03062 | 45% | S11 | — | — | 44 |
| P-03179 | 45% | S05 | GI-04 | improved | 52 |
| P-03268 | 45% | S15 | DT-01 | improved | 56 |
| P-03392 | 45% | S15 | GI-04 | improved | 52 |
| P-03193 | 44% | S13 | DT-01 | improved | 53 |